{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:04:48Z","timestamp":1780664688970,"version":"3.54.1"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["17MCPRP33400175"],"award-info":[{"award-number":["17MCPRP33400175"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001857"],"award-info":[{"award-number":["UL1TR001857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026326","name":"American Society of Health-System Pharmacists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ABCD-GENE (Age, Body Mass Index, Chronic Kidney Disease, Diabetes Mellitus, and Genotyping) score is a tool used to identify increased thrombotic risk in clopidogrel-treated patients. We evaluated the association between a low ABCD-GENE score (&lt;10) and Bleeding Academic Research Consortium (BARC)-defined bleeding among prasugrel or ticagrelor and clopidogrel-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was an IRB-approved retrospective cohort study of patients who underwent percutaneous coronary intervention (PCI) and\n                      <jats:italic toggle=\"yes\">CYP2C19<\/jats:italic>\n                      genotyping. The primary outcome was time to first bleed of any severity within 1 year. Time to first major bleed, defined by BARC 3a, 3b, 3c, or 5 criteria, and major adverse cardiovascular events (MACE) were secondary outcomes. BARC bleeding events were compared between prasugrel or ticagrelor and clopidogrel-treated patients and stratified by the ABCD-GENE score threshold of \u226510. Kaplan-Meier and multivariable Cox proportional hazards model were used for time-to-event analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 2547 patients, 1760 were in the low score group, and 787 were in the high score group. Kaplan-Meier analysis showed that any bleeding (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.008) and major bleeding (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.015) were less for those with a low score compared to a high score. Among those in the low score group, any bleeding (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001) and major bleeding (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.022) were lower with clopidogrel versus prasugrel or ticagrelor. However, the ABCD-GENE score was not independently associated with bleeding in the Cox model. No difference in MACE was observed by treatment in the low score group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ABCD-GENE score was associated with BARC bleeding, yet other variables had a greater impact such as history of GI bleed, anticoagulation, P2Y12 inhibitor, and age. Patients with a low score who received prasugrel or ticagrelor had more bleeding versus clopidogrel. Our findings support further evaluation of the ABCD-GENE score as a tool for guided P2Y12 inhibitor de-escalation post-PCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10742484261457268","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:25:13Z","timestamp":1780406713000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-3751","authenticated-orcid":false,"given":"James C.","family":"Coons","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"},{"name":"UPMC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Polkowski","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Prebehalla","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anson Conrad","family":"Smith","sequence":"additional","affiliation":[{"name":"UPMC"},{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-2339","authenticated-orcid":false,"given":"Philip E.","family":"Empey","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.064473"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2022-0057"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001257"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp157"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.040"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2020.01.226"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2024.08.027"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.015"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.0783"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000787"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/10742484221143246"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2526"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.08.003"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2612"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2024.06.020"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-20-01197"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484261457268","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10742484261457268","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484261457268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:16:31Z","timestamp":1780661791000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10742484261457268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":21,"alternative-id":["10.1177\/10742484261457268"],"URL":"https:\/\/doi.org\/10.1177\/10742484261457268","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"10742484261457268"}}